Topic Hub
14 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 14 of 14 clinical reviews.
Step-by-step caregiver guidance for administering Egrifta (tesamorelin) subcutaneous injections to adolescents aged 12 to 17, including reconstitution, injection technique, storage, missed-dose protocol, and safety monitoring.
Read clinical reviewA comprehensive clinical review of tesamorelin's effects on growth, puberty, body composition, and metabolic health in adolescents aged 12 to 17, with safety data and prescribing guidance.
Read clinical reviewA clinician-reviewed guide to managing tesamorelin therapy in adolescents aged 12-17, covering school schedules, physical activity, injection timing, storage, and academic performance considerations.
Read clinical reviewA clinician-reviewed guide to tesamorelin (Egrifta) use in patients 65 and older, covering dosing adjustments, safety monitoring, IGF-1 targets, and how to manage the transition from adult to geriatric care protocols.
Read clinical reviewComplete caregiver guide to administering Egrifta (tesamorelin) to adults 65 and older: reconstitution steps, injection technique, storage rules, side-effect monitoring, and when to call the prescriber.
Read clinical reviewA clinical guide to tesamorelin (Egrifta) use in adults aged 65 and older, covering physical activity interactions, fall risk, cognitive considerations, social engagement, and monitoring protocols backed by primary-source evidence.
Read clinical reviewA clinical deep-dive into how tesamorelin (Egrifta) affects older adults aged 65+, covering GH-IGF-1 axis changes, visceral fat reduction, cognitive effects, safety signals, and dosing considerations specific to geriatric patients.
Read clinical reviewA clinical deep-dive into tesamorelin (Egrifta) use in patients aged 65 and older, covering off-label rationale, trial data, dosing adjustments, safety signals, and how geriatric physiology changes the risk-benefit calculation.
Read clinical reviewA comprehensive review of tesamorelin (Egrifta) off-label use in pediatric patients under age 12, covering pharmacology, available evidence, safety signals, and what clinicians should know before considering this growth-hormone-releasing hormone analog in young children.
Read clinical reviewTesamorelin (Egrifta) carries no FDA approval for patients under 18. This guide covers the pharmacology, the sparse pediatric evidence, dosing considerations, safety signals, and the clinical decision framework HealthRX physicians apply when evaluating adolescent off-label requests.
Read clinical reviewComplete caregiver guidance for administering Egrifta (tesamorelin) to children under age 12, including reconstitution steps, injection technique, storage, side effects, and when to call the prescribing clinician.
Read clinical reviewA thorough clinical review of tesamorelin (Egrifta) use in children under 12, covering growth plate risks, IGF-1 physiology, regulatory status, and when GHRH analogs are appropriate in pediatric patients.
Read clinical reviewA clinician-reviewed guide covering how tesamorelin (Egrifta) affects school performance, physical activity, sleep, and daily routines in children under 12, including dosing context, side-effect monitoring, and coordination with school staff.
Read clinical reviewA clinical guide to transitioning pediatric patients under 12 from tesamorelin-adjacent growth hormone axis therapy into adult endocrine care, covering FDA labeling, GH deficiency guidelines, safety monitoring, and care coordination protocols.
Read clinical review